Prostate cancer
mCRPC: novel and emerging agents

Walt (73 years old)

Walt, 73 years old, loves a good dinner with his wife and they often attend wine-tasting nights. He was diagnosed with PCa 7 years ago.

Medical history:

  • 7 years ago: RP for PCa (pT3bN0, ISUP grade 5, postoperative PSA <0.1 ng/ml)
  • 6 years ago: salvage RT for rising PSA (0.53 ng/ml)
  • 5 years ago: ADT started because of rising PSA (7 ng/ml), no metastases on conventional imaging
  • 2 years ago: progression to mCRPC (bone), treatment with abiraterone started

 

Current situation:

  • Ongoing treatment with ADT + abiraterone
  • Rising PSA: from 0.9 ng/ml to 3.9 ng/ml
  • ECOG PS: 1
  • Back pain
  • MRI spine:
    • Progression of existing bone lesions and new bone lesions in multiple vertebrae
    • Enlarging soft tissue component at Th9 causing spinal cord compression
    • Neurosurgical decompression was performed
  • Histology from neurosurgical decompression: metastatic poorly-differentiated PCa
  • Somatic BRCA2 mutation

Which of the following treatment options would you choose for this patient, following local management of the spinal cord compression?